HOME >> BIOLOGY >> NEWS
Making sense of Marfan syndrome

In the July 15 issue of Genes & Development, Drs. Massimo Caputi, Raymond Kendzior Jr. and Karen Beemon of Johns Hopkins University report on their determination of a molecular mechanism of Marfan syndrome pathogenesis a discovery that may end the decade-long debate over how this relatively common genetic disorder develops.

Originally characterized in 1896, Marfan syndrome is a heritable disorder of the connective tissue, which usually affects the skeletal, respiratory, cardiovascular, and ocular systems, and is commonly associated with tall stature and markedly long limbs. In 1991 scientists discovered that Marfan syndrome is caused by mutations in the fibrillin 1 (FBN1) gene.

Now, more than a decade later, Dr. Beemon and colleagues are lending new insight into the mechanism by which some mutations in the FBN1 gene result in Marfan syndrome.

The FBN1 gene encodes the fibrillin protein, a component of the rod-like microfibrils that comprise the connective tissue. Mutations in the FBN1 gene that compromise fibrillin protein activity can, in turn, affect the integrity of the connective tissue and give rise to the symptoms associated with Marfan syndrome.

The FBN1 gene has 65 exons, or coding regions, that are separated by non-coding introns, which are removed from, or "spliced out of," the pre-mRNA transcript during nuclear processing. In the early 1990s, a Marfan syndrome patient was found to harbor a mutation in FBN1 exon 51 that causes the nuclear splicing machinery to skip exon 51 entirely. Skipping exon 51 is problematic, though, as exon 51-skipped fibrillin proteins have compromised function because the region encoded by exon 51 is critical for normal fibrillin protein activity.

Dr. Beemon and colleagues demonstrate that exon 51 skipping is the result of the disruption of an exonic splicing enhancer (ESE), a DNA sequence within the FBN1 gene that increases splicing efficiency. The scientists discovered that other type
'"/>

Contact: Heather Cosel
coselpie@cshl.org
Cold Spring Harbor Laboratory
14-Jul-2002


Page: 1 2

Related biology news :

1. Making a friendlier mosquito
2. Making sense of the brains mind-boggling complexity
3. Making protein nanostructures
4. Making the most of stem cells
5. Making of mouse marks move toward mitochondrial medicine
6. Making new muscle: Researchers in Rome produce a mouse that can regenerate its tissues
7. Making sense of bacterial biodiversity
8. Making sense of the genome
9. Making a safer anthrax vaccine using spinach
10. A new twist on an age-old problem: Making knee replacements last
11. Making the most of lymphopenia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: